Merck (MRK) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Merck reported revenue of $15.53 billion for Q1 2025, a decrease of 1.6% year-over-year, with an EPS of $2.22, up from $2.07 in the same quarter last year, exceeding both revenue and EPS consensus estimates [1][2] Financial Performance - Revenue of $15.53 billion compared to Zacks Consensus Estimate of $15.39 billion, resulting in a surprise of +0.93% [1] - EPS of $2.22 compared to consensus estimate of $2.15, leading to an EPS surprise of +3.26% [1] Key Metrics - Merck's stock has returned -10.6% over the past month, underperforming the Zacks S&P 500 composite's -5.1% change [3] - Current Zacks Rank for Merck is 3 (Hold), indicating potential performance in line with the broader market [3] Oncology Sales - Keytruda U.S. sales were $4.31 billion, below the average estimate of $4.47 billion, but up 4.6% year-over-year [4] - Keytruda International sales were $2.90 billion, compared to the $3.08 billion estimate, reflecting a 2.4% year-over-year increase [4] - Lynparza U.S. sales reached $145 million, exceeding the $121.96 million estimate, with a year-over-year increase of 7.4% [4] - Lynparza International sales were $168 million, below the $178.66 million estimate, but up 7% year-over-year [4] - Total Keytruda sales amounted to $7.21 billion, compared to the $7.55 billion estimate, marking a 3.7% year-over-year increase [4] Other Product Sales - Zerbaxa sales in Hospital Acute Care were $70 million, surpassing the $63.07 million estimate, with a 25% year-over-year increase [4] - Animal health sales were $1.59 billion, slightly below the $1.61 billion estimate, but up 5.1% year-over-year [4] - Prevymis sales were $208 million, exceeding the $190.69 million estimate, with a significant year-over-year increase of 19.5% [4] - Reblozyl sales reached $119 million, above the $101.77 million estimate, reflecting a substantial year-over-year increase of 67.6% [4]